Announcements
- Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
- Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
- Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
- Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
- Pacira to Report 2023 Financial Results on Thursday February 29, 2024
- Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
- Pacira BioSciences Awarded Brand Pharmaceuticals Agreement With Premier, Inc.
- Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2023 Revenues
- Pacira BioSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 46.52m |
Free float | 45.94m |
P/E (TTM) | 40.08 |
Market cap | 1.27bn USD |
EPS (TTM) | 0.6789 USD |
Data delayed at least 15 minutes.
More ▼